AI-generated analysis. Always verify with the original filing.
BioAtla reported its Q4 and full-year 2025 financial results, announced a formal process to monetize assets, and implemented a restructuring plan to reduce expenses and extend its cash runway.
Event Type
Disclosure
Mandatory
Variant
8-K
of this Current Report, including Exhibit 99.1 attached hereto, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amen
of this Current Report, including Exhibit 99.2 attached hereto, shall not be incorporated by reference into any filing under the Securities Act or the Exchange
Financial Statements and Exhibits. (d) Exhibits | | | | |---|---|---| | Exhibit | | Description | | 99.1 | | Press Release dated March 31, 2026 | | 99.2 | | Bio
| Metric | Value | Basis |
|---|---|---|
| Research and Development Expenses | $8.00 | |
| Research and Development Expenses | $43.60 | |
| Collaboration and Other Revenue | $2.00 | |
| General and Administrative Expenses | $3.30 | |
| General and Administrative Expenses | $17.70 | |
| Net Loss | $9.80 | |
| Net Loss | $59.60 |